30 results about "Liquid oral" patented technology

The disclosure provides liquid compositions configured for oral use, the liquid composition comprising water in an amount of about 40% by weight or higher, based on total weight of the composition, a flavoring agent or an active ingredient or both a flavoring agent and an active ingredient, and one or more additional components selected from the group consisting of sweeteners, humectants, and alkali metal salts, wherein the composition has a water activity (Aw) of about 0.85 or lower. The liquid compositions are generally suitable for spraying into the oral cavity.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The object of the present invention is to provide a non-invasive agent that, in particular, exhibits a skin-improving effect and reduces the visible signs of aging. For this purpose, the invention provides a liquid oral composition as a food supplement or dietary food, comprising liquid marine hydrolyzed collagen peptides obtained from cod skin.

The present invention aims to provide a liquid oral composition that can suppress the reduction in flavor expression caused by glycyrrhizic acid or its salts by incorporating acyl amino acids or their salts. [Solution] A liquid oral composition comprising: (A) component: at least one selected from the group consisting of glycyrrhizic acid and its salts; (B) component: at least one selected from the group consisting of acyl amino acids and their salts; and (C) component: a fragrance, wherein the ratio of the content of component (A) to the content of component (B) is 0.625 to less than 2.2 when component (B) contains acyl sarcosine and its salts, and 0.03 to less than 5 when component (B) does not contain acyl sarcosine and its salts, and substantially free of ethyl alcohol.

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

The utility model discloses a multifunctional drainage liquid oral taking cup, and relates to the technical field of drinking cups. The multifunctional drainage liquid oral taking cup comprises a cup body and a cup cover, the cup cover covers the top of the cup body, a drainage liquid injection opening and a drainage liquid direct drinking opening are formed in the two sides of the top of the cup cover respectively, the drainage liquid injection opening and the drainage liquid direct drinking opening are separated, unfiltered drainage liquid can be prevented from being directly drunk, and the multifunctional drainage liquid oral taking cup is provided with a double-drinking-opening flip cover design. Daily sealing protection of the drainage liquid injection opening and the drainage liquid direct drinking opening is achieved, particularly, the sealing rubber plug is arranged in the outer cover covering the drainage liquid direct drinking opening, the sealing performance is further improved, the smell of the drainage liquid can be covered, the discomfort of a patient taking the drainage liquid is relieved, and the drainage liquid can be prevented from being poured easily. And besides the use of medical consumables is saved, the convenience of filtering the drainage liquid is also increased, and the backflow prevention design can also prevent a patient from pouring out the drainage liquid from the drainage liquid injection port by mistake for drinking, so that the use is convenient.

The present invention aims to provide a liquid oral composition that does not contain ethyl alcohol and can sufficiently suppress the formation of precipitates during high-temperature storage. [Solution] The present invention provides a liquid oral composition that is substantially free of ethyl alcohol and comprises (A) component: dextranase and (B) component: xanthan gum, preferably further comprising (C) component. It is preferable that the content of component (A) is 0.0077 to 1.54% by mass, the content of component (B) is 0.01 to 1.0% by mass, and the mass ratio of the content of component (A) to the content of component (B) ((A) / (B)) is 0.6 to 150.

This invention provides a liquid oral composition with excellent retention properties for dodecylpyridinium chloride. [Solution] The liquid oral composition contains dodecylpyridinium chloride and a compound having a hydroxyl group.

The application provides a sugar alcohol solvent and its application in preparation of a product containing ginkgo leaf extract, and belongs to the technical field of food and health care products. The sugar alcohol solvent comprises xylitol, and the mass percentage of xylitol in the sugar alcohol solvent is 30-50%. The sugar alcohol solvent is safe and non-toxic, has simple preparation process and low cost, can be used as a solubilizing solvent for the ginkgo leaf extract, can improve the solubility of the ginkgo leaf extract without affecting the stability and biological activity of ginkgolides and ginkgo flavones in the ginkgo leaf extract, can be used as an intermediate purification solvent for preparation of ginkgolide monomers, is safe and non-toxic, and can be used as a new solvent for the ginkgo leaf extract to prepare a liquid oral ginkgo leaf extract, so that liquid health care is realized, and safe drug delivery is realized for diagnosis and treatment of cardiovascular and cerebrovascular diseases of special groups (such as diabetic patients).

The present invention aims to provide a colorant composition that contains core-shell particles encapsulating a colorant and that can be used for forming a pattern such as a line in a liquid such as a drink, as well as a liquid oral composition containing the colorant composition and a production method therefor, and a method for forming a pattern in a liquid. The present invention relates to a colorant composition containing a first liquid and core-shell particles, the core-shell particles each including a core and a shell that encapsulates the core, the core containing an oily component and a colorant, the shell containing a cationic polymer, the cationic polymer being edible, the core-shell particles being dispersed in the first liquid.

Liquid oral pilocarpine formulations are described herein. Methods of using the liquid oral pilocarpine formulations are also provided.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The present invention provides methods for treating a genetic neurodevelopmental disorder such as Rett syndrome, comprising administering to a subject in need thereof a liquid oral dosage formulation comprising a therapeutically effective amount of ANAVEX2-73.

A method reduces postprandial glucose from a meal. The method includes orally administering to an individual a composition containing medium chain triglycerides (MCT) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The postprandial glucose is reduced relative to postprandial glucose from (i) postprandial glucose from administration of an identically formulated composition containing MCTs at approximately the same time as the administration of the meal and (ii) postprandial glucose from administration of the meal without any MCTs within about one hour before or within about one hour afterward. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.

A micronutrient composition for infants and children from 6 months of age, characterized in that it is a liquid oral formulation containing the following main active ingredients: microencapsulated lutein, microencapsulated zeaxanthin, proanthocyanidins, anthocyanins, taurine, zinc, vitamin A and vitamin E, wherein the composition serves to support healthy retinal development in infants, to relieve visual fatigue and to build an antioxidant defense system in the eye.

The present invention relates to stable liquid oral pharmaceutical formulations of cannabidiol (CBD) and also discloses methods of producing stabilized formulations of cannabidiol using cannabidiol from a synthetic source. The stable formulations of the present invention comprise of synthetic CBD and one or more pharmaceutically acceptable excipients selected from solvents, oils, organoleptic modifiers, buffers, surfactants etc.

A method increases production of ketones derived from oral consumption of medium chain triglycerides (MCT) by an individual. The method includes orally administering to the individual a composition containing the MCTs and then subsequently orally administering to the individual a meal at least about ten minutes after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The ketone production is increased relative to ketone production from oral administration of the MCTs and the meal at approximately the same time. The meal can be breakfast. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.

Disclosed herein are tooth whitening wipes comprising an absorbent fabric substrate made of bamboo fibers, wherein the absorbent fabric substrate is impregnated with a liquid oral care composition comprising phytic acid or a salt thereof. Also disclosed herein are methods of whitening teeth by removing or preventing stains.

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

The present invention relates to a stable, bioavailable, oral lipophilic nutrient composition comprising RR-zeaxanthin, curcuminoids, and / or lutein, along with nutraceutically acceptable excipients. In particular, the present invention provides a stable, bioavailable liquid oral composition comprising zeaxanthin isomers, curcuminoids, and / or lutein. The stable, bioavailable lipophilic nutrient composition of R, R-zeaxanthin, curcuminoids, and / or lutein is used for ophthalmic care, preferably for age-related eye diseases (AREDS), Age-related Macular degeneration (AMD), Visual dysfunction, Retinopathy, and other Eye diseases and disorders. The present invention further provides a process for preparing a nutraceutically stable and bioavailable lipophilic nutrient composition comprising zeaxanthin isomers, curcuminoids, and / or lutein.

A method reduces postprandial glucose from a meal. The method includes orally administering to an individual a composition containing medium chain triglycerides (MCT) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The postprandial glucose is reduced relative to postprandial glucose from (i) postprandial glucose from administration of an identically formulated composition containing MCTs at approximately the same time as the administration of the meal and (ii) postprandial glucose from administration of the meal without any MCTs within about one hour before or within about one hour afterward. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.

A method increases production of ketones derived from oral consumption of medium chain triglycerides (MCT) by an individual. The method includes orally administering to the individual a composition containing the MCTs and then subsequently orally administering to the individual a meal at least about ten minutes after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The ketone production is increased relative to ketone production from oral administration of the MCTs and the meal at approximately the same time. The meal can be breakfast. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.

The present invention relates to oral liquid formulation of famotidine or pharmaceutically acceptable salt thereof. The present invention also relates to the process for the preparation of said liquid formulation. The liquid formulation is in the form of solution, suspension, powder for suspension or powder for solution.

The present invention aims to provide a liquid oral composition that contains no ethyl alcohol and in which the generation of precipitates during storage at high temperatures can be sufficiently suppressed. Specifically, the present invention provides a liquid oral composition that is substantially free of ethyl alcohol, and comprises dextranase as a component (A), and xanthan gum as a component (B), and preferably further comprises a component (C). It is preferable that at least one of the following conditions is satisfied: the content of component (A) is 0.0077 to 1.54% by mass; the content of component (B) is 0.01 to 1.0% by mass; and the mass ratio ((A) / (B)) of the content of component (A) to the content of component (B) is 0.6 to 150.

Disclosed herein are teeth whitening wipes comprising an absorbent tissue substrate made with bamboo fiber, wherein the absorbent tissue substrate is impregnated with a liquid oral care composition that comprises phytic acid or a salt thereof. Also disclosed herein are methods of whitening teeth by removing or preventing stains.

The present invention aims to provide a liquid oral composition that has an astringent sensation, effectively suppresses discoloration over time, and improves the sour taste during use. [Solution] The present invention relates to a liquid oral composition comprising (A) component: pyridoxine or a salt thereof, (B) component: glycerin, and (C) component: at least one selected from the group consisting of sorbitol, propylene glycol, and polyethylene glycol, wherein the ratio of the content (mass%) of component (B) to the content (mass%) of component (C) is less than 1, more preferably (D) component: a predetermined sweetener, and even more preferably (E) component: at least one selected from the group consisting of tocopherol acetate and tocopherol nicotinate.

The present application provides a liquid oral composition which has a good feeling of use, can exhibit an appropriate retention feeling, and can suppress the generation of deposits at high temperatures. A liquid oral composition characterized by containing (A) glycyrrhizic acid or a salt thereof and (B) vitamin E, in which the content of component (A) is 0.05-0.20% by mass, the content of component (B) is 0.01-1% by mass, and the content of water is 45-90% by mass.